Shirley Williams
Rebecca Kush, Ph.D. CDISC
512.341.9885
www.cdisc.org
CDISC
Releases New Submissions Domain Models
Austin, TX - 27 November
2001 -The Clinical
Data Interchange Standards Consortium (CDISC)
announced the publication of Version 2.0 of
the CDISC Submissions Domain Models. These new
models were developed by the Submissions Data
Standards (SDS) team, which includes more than
20 active members representing major pharmaceutical
companies and contract research organizations
(CROs).
"To see a set of standards
be developed to this level by representatives
of companies that have different ways of doing
things is truly remarkable," said Fred
Wood, Procter & Gamble Pharmaceuticals.
The Version 2.0 domains were also developed
with active participation of the FDA liaisons
to CDISC, and have been tested with standard
computer applications that are being used within
the FDA.
"The Version 2.0 SDS
domains have been designed for broad adoption
throughout the industry," said SDS Team
Leader, Wayne Kubick. "We believe these
models have addressed most of the ambiguities
and concerns that were raised by early adopters
of Version 1.0, and will serve as a solid foundation
for our future submission modeling efforts."
It is important to CDISC that their modeling
efforts support worldwide standards.
"CDISC espouses the cause
of developing global standards -- a challenge
we willingly face. This is a logical step after
having implemented standards in our local environment,"
said Dr. Johann Bruening, Head of Global Standards
for Clinical Data, Schering AG.
Among the many improvements
in the SDS Version 2.0 domains are revisions
to the core and non-core variable contents,
definitions and names, the addition of standard
formats and decodes [including support for the
Logical Observation Identifier Names and Codes
(LOINC) database maintained by the Regenstrief
Institute], compatibility with the ICH E2B standard
for adverse event reporting, an improved presentation
format, and expanded documentation. Version
2.0 also includes two new alternative vertical
representations of Vital Signs and ECG data,
in addition to the horizontal representations
originally prepared for the Version 1.0 models.
"We believe the vertical
representations will be increasingly useful
as the FDA moves to standard database applications
for data review and analysis, while the horizontal
representations are more historically suited
to working with flat data files," said
Chris Tolk of Bayer Corporation, Pharmaceutical
Division.
"Covance believes that
submission data modeling is essential to improving
communication of clinical trial data between
pharma companies, CROs and regulatory authorities,"
said Michael Walega, who represents Covance
on the CDISC Industry Advisory Board. "We
continue to actively support the SDS team in
its efforts to develop these improved models."
As a related CDISC activity,
their Analysis Dataset Modeling team (ADaM)
recently published a draft set of guidelines
for the submission of analysis datasets and
documentation and a strawman metadata model
for a percent change from baseline statistical
analysis. Both documents are posted on the CDISC
website and are currently undergoing review
and testing by FDA statisticians.
CDISC encourages adoption
of these models both for regulatory submissions
and for use within sponsor organizations. CDISC
requests feedback from industry on the SDS and
ADaM models through its website discussion facility.
The industry feedback will be used to improve
future versions of the models. The SDS group
is also working on additional domain models
for pharmacokinetics data and other safety and
efficacy domains.
CDISC is an open, multidisciplinary,
non-profit organization committed to the development
of worldwide standards to support the electronic
acquisition, exchange, submission and archiving
of clinical trials data and metadata for medical
and biopharmaceutical product development. The
CDISC mission is to lead the development of
global, vendor-neutral, platform-independent
standards to improve data quality and accelerate
product development in the pharmaceutical industry.
Additional information, including
downloadable copies of the Version 2.0 SDS models,
can be found on the CDISC website at www.cdisc.org.
###
|